FDA Clears Spectral AI's DeepView System for Burn Care, Paving Way for Commercial Launch
MDAI has more than doubled off its 52-week low of $1.18.
Summary
Spectral AI has received FDA De Novo Classification for its DeepView System for burn indication, allowing immediate commercial distribution in the United States. This is a critical regulatory milestone for the company's core predictive AI medical device. The clearance follows earlier positive clinical trial results and significant non-dilutive funding from BARDA. This development is crucial, especially after the company reported a sharp decline in Q1 2026 revenue and increased cash burn, providing a clear path to revenue generation and addressing recent financial concerns.
At the time of this announcement, MDAI was trading at $2.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.3M. The 52-week trading range was $1.18 to $3.21. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.